AfaSci Overview

  • Year Founded
  • 2003

Year Founded

  • Status
  • Private

  • Employees
  • 17

Employees

  • Latest Deal Type
  • Grant

  • Latest Deal Amount
  • $2.3M

  • Investors
  • 3

AfaSci General Information

Description

Developer of peptide and small molecule therapies intended for unmet needs in the fields of pain and neurology. The company's services include pre-clinical tests based on cognitive, sleep monitoring and deprivation, depression, epileptic convulsion, stroke, pharmacokinetics, analgesics, and electrophysiology, enabling scientists to develop tools and therapies based on research.

Contact Information

Website
www.afasci.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 2633 Martinez Drive
  • Burlingame, CA 94010
  • United States
+1 (415)
Primary Industry
Drug Discovery
Other Industries
Discovery Tools (Healthcare)
Biotechnology
Vertical(s)
Corporate Office
  • 2633 Martinez Drive
  • Burlingame, CA 94010
  • United States
+1 (415)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

AfaSci Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Grant 01-Jan-2023 $2.3M Completed Generating Revenue
3. Debt - PPP 30-Apr-2020 Completed Generating Revenue
2. Grant 01-Jan-2019 $17.7M Completed Generating Revenue
1. Early Stage VC Completed Startup
To view AfaSci’s complete valuation and funding history, request access »

AfaSci Patents

AfaSci Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-3843731-B1 Ion channel inhibitory compounds for treating hypersensitive cough Active 28-Aug-2018
EP-3843731-C0 Ion channel inhibitory compounds for treating hypersensitive cough Active 28-Aug-2018
EP-3843731-A1 Methods of treating hypersensitive cough or itching using ion channel inhibitory compounds Active 28-Aug-2018
EP-3843731-A4 Methods of treating hypersensitive cough or itching using ion channel inhibitory compounds Active 28-Aug-2018
JP-2024096843-A Methods of treating hypersensitive cough or itching using ion channel inhibitory compounds Active 28-Aug-2018 A61K31/438
To view AfaSci’s complete patent history, request access »

AfaSci Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

AfaSci Investors (3)

Investor Name Investor Type Holding Investor Since Participating Rounds
National Institutes of Health Government
U.S. Department of Health and Human Services Government
Luminor International Management Venture Capital Minority
To view AfaSci’s complete investors history, request access »

AfaSci FAQs

  • When was AfaSci founded?

    AfaSci was founded in 2003.

  • Where is AfaSci headquartered?

    AfaSci is headquartered in Burlingame, CA.

  • What is the size of AfaSci?

    AfaSci has 17 total employees.

  • What industry is AfaSci in?

    AfaSci’s primary industry is Drug Discovery.

  • Is AfaSci a private or public company?

    AfaSci is a Private company.

  • What is AfaSci’s current revenue?

    The current revenue for AfaSci is .

  • Who are AfaSci’s investors?

    National Institutes of Health, U.S. Department of Health and Human Services, and Luminor International Management have invested in AfaSci.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process